Dr Reddy's Labs launch Ziprasidone Mesylate for injection

Dr Reddy's Laboratories Ltd announced the launch of Ziprasidone Mesylate for injection, 20 mg (base)/ml single-dose Vials in US market.

Ziprasidone Mesylate for injection, 20 mg (base)/ml single-dose Vials is a therapeutic generic equivalent of Geodon (Ziprasidone Mesylate) injection, 20 mg/ml. It was also previously approved by US Food & Drug Administration (USFDA). Ziprasidone is used to treat occurrences of severe agitation in patients with Schizophrenia.

Marc Kikuchi, Chief Executive Officer of North America Generics, Dr Reddy's Laboratories believes that after the launch of this injection, patients will be able to benefit from access to affordable medicines. This has enabled the company to diversify its portfolio growth within the hospital segment. According to IQVIA Health, Geodon brand had US sales of approximately US $21.8 million MAT for the most recent twelve months ending in January 2020.

Dr Reddy's Laboratories is a multinational pharmaceutical company manufacturing and marketing a wide range of pharmaceuticals in India and overseas.

On Tuesday, the stock of the company closed at Rs 2,791.15, down by 1.25 per cent or Rs 35.25 per share. The intraday high was Rs 2,902 and intraday low was Rs 2,759.55. The 52-week high is Rs 3,363 and52-week low is Rs 2,352 on BSE.